# Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia

> **NCT01065038** · PHASE3 · COMPLETED · sponsor: **AOP Orphan Pharmaceuticals AG**

## Conditions studied

- Essential Thrombocythaemia

## Interventions

- **DRUG:** Anagrelide
- **DRUG:** Hydroxyurea

## Key facts

- **NCT ID:** NCT01065038
- **Lead sponsor:** AOP Orphan Pharmaceuticals AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2010-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01065038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01065038, "Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01065038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*